Regencell Bioscience Holdings Limited
RGCHealthcare|Drug Manufacturers - Specialty & Generic|HK
$5.27
+0.00 (+0.00%)
DCF Value
$0.03
Tangible Book / Share
$0.03
Cash / Share
$0.03
About
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Stock Price
-60.3%(1Y)
1M
-30.9%
3M
-2.6%
6M
-82.0%
YTD
-74.9%
1Y
-61.9%
3Y
+1281.1%
5Y
+802.1%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$2.61B
Employees10
CEOYat-Gai Au
IPO DateJul 16, 2021
Beta1.43
52-Week Range$4.51 – $69
Avg Volume279,248
ExchangeNASDAQ
Websiteregencellbioscience.com
Ownership
Float3.5%
Shares Outstanding495.9M
Recent Insider Trades
LO WILLIAM WING YAN DRDISPOSED
May 27, 202670,600 shares @ $0.84
HUI EVANA YEE WAHDISPOSED
May 27, 202619,000 shares @ $0.25
LO WILLIAM WING YAN DROTHER
Mar 18, 2026592,230 shares @ $0.84
LO MARGARET HOOR HANOTHER
Mar 18, 20260 shares
LO MARGARET HOOR HANOTHER
Mar 18, 2026592,230 shares @ $17.40
Peers
Recent News
Regencell Bioscience (NASDAQ:RGC) Releases Earnings Results
Oct 8, 2026 · defenseworld.net
RGC Resources, Inc. Declares Quarterly Dividend
Sep 28, 2026 · globenewswire.com
RGC Resources: More Likely To Appeal More To Income-Focused Investors
Aug 18, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 04:31 AM